2011 Up-Date of the Consensus Statement of the Spanish Society of Rheumatology on Osteoporosis

CEBM CfEBM. Oxford centre for evidence-based medicine-levels of evidence (March 2009). Available from: http://www.cebm.net/index.aspx?o=1025; 2009 [updated March 2009; cited in November 2009]. 2001, Osteoporosis prevention, diagnosis, and therapy, JAMA, 285, 785, 10.1001/jama.285.6.785 National Osteoporosis Guideline Group. NOGG. Sheffield: World Health Organization Collaborating Centre for metabolic bone diseases; Available from: http://www.shef.ac.uk/NOGG/; 2010 [updated January 2010; cited in March 2011]. Robinson, 2002, Refractures in patients at least forty-five years old. A prospective analysis of twenty-two thousand and sixty patients, J Bone Joint Surg Am, 84-A, 1528, 10.2106/00004623-200209000-00004 1998, Guidelines for preclinical evaluation and clinical trials in osteoporosis Melton, 1997, Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation, J Bone Miner Res, 12, 16, 10.1359/jbmr.1997.12.1.16 Brown, 2002, 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada, CMAJ, 167, S1 Scottish Intercollegiate Guidelines Network. Available from: www.sign.ac.uk [updated May 2011; cited in May 2011]. Melton, 1995, How many women have osteoporosis now?, J Bone Miner Res, 10, 175, 10.1002/jbmr.5650100202 Herrera, 2003, Recomendaciones de manejo clínico del paciente mayor de 50 años con fractura osteoporótica, REEMO, 12, 125 Kanis, 2007, The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women, Osteoporos Int, 18, 1033, 10.1007/s00198-007-0343-y Kanis, 2008, FRAX and the assessment of fracture probability in men and women from the UK, Osteoporos Int, 19, 385, 10.1007/s00198-007-0543-5 Kanis, 2002, Diagnosis of osteoporosis and assessment of fracture risk, Lancet, 359, 1929, 10.1016/S0140-6736(02)08761-5 Kanterewicz, 2010, Anamnesis. Exploración física. Estudio analítico, 65 Cooper, 1993, The epidemiology of vertebral fractures. European Vertebral Osteoporosis Study Group, Bone, 14, S89, 10.1016/8756-3282(93)90358-H De Laet, 2005, Body mass index as a predictor of fracture risk: a meta-analysis, Osteoporos Int, 16, 1330, 10.1007/s00198-005-1863-y Brown, 2006, Canadian consensus conference on osteoporosis, 2006 update, JOGC, S95 Tannenbaum, 2002, Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women, J Clin Endocrinol Metab, 87, 4431, 10.1210/jc.2002-020275 Cerda Gabaroi, 2010, Search for hidden secondary causes in postmenopausal women with osteoporosis, Menopause, 17, 135, 10.1097/gme.0b013e3181ade8e5 Eastell, 2008, Biomarkers of bone health and osteoporosis risk, Proc Nutr Soc, 67, 157, 10.1017/S002966510800699X Garnero, 2009, Bone markers in osteoporosis, Curr Osteoporos Rep, 7, 84, 10.1007/s11914-009-0014-3 Delmas, 2000, The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation, Osteoporos Int, 11, S2, 10.1007/s001980070002 Eastell, 2006, Development of an algorithm for using PINP to monitor treatment of patients with teriparatide, Curr Med Res Opin, 22, 61, 10.1185/030079905X75096 Diez-Perez, 2008, Inadequate responders to osteoporosis treatment: proposal for an operational definition, Osteoporos Int, 19, 1511, 10.1007/s00198-008-0659-2 Klotzbuecher, 2000, Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis, J Bone Miner Res, 15, 721, 10.1359/jbmr.2000.15.4.721 Naves, 2003, The effect of vertebral fracture as a risk factor for osteoporotic fracture and mortality in a Spanish population, Osteoporos Int, 14, 520, 10.1007/s00198-003-1405-4 Naves, 2005, Determinants of incidence of osteoporotic fractures in the female Spanish population older than 50, Osteoporos Int, 16, 2013, 10.1007/s00198-005-1983-4 Kanis, 2005, Assessment of fracture risk, Osteoporos Int, 16, 581, 10.1007/s00198-004-1780-5 Hasserius, 2003, Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study, Osteoporos Int, 14, 61, 10.1007/s00198-002-1316-9 Grados, 2009, Radiographic methods for evaluating osteoporotic vertebral fractures, Joint Bone Spine, 76, 241, 10.1016/j.jbspin.2008.07.017 U.S. Preventive Services Task Force. Guide to clinical preventive services. Available from: http://www.ahrq.gov/clinic/uspstfix.htm; 2010 [updated 2010; cited in May 2011]. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Available from: www.nof.org; 2008 [updated 2008; cited in April 2011]. International Society for Clinical Densitometry (ISCD). Canadian physician pocket guide to BMD testing. Available from: http://www.iscd.org/Visitors/PDFs/ISCD-CANADIANPanelOfficialPositions-BMDcard.pdf; 2004 [updated 2004; cited in April 2011]. Lewiecki, 2009, The official positions of the International Society for Clinical Densitometry: perceptions and commentary, J Clin Densitom, 12, 267, 10.1016/j.jocd.2009.03.098 2007, Documento de Consenso 2006 de la Sociedad Española de Reumatología sobre la osteoporosis posmenopáusica, Reumatol Clin, 3, 26 Kanis, 2008, European guidance for the diagnosis and management of osteoporosis in postmenopausal women, Osteoporos Int, 19, 399, 10.1007/s00198-008-0560-z González Macías, 2008, Guías de práctica clínica en la osteoporosis postmenopáuisca, glucocorticoidea y del varón. Sociedad Española de Investigación Ósea y del Metabolismo Mineral, Rev Clin Esp, 28, 1, 10.1016/S0014-2565(08)71780-6 Kanis, 1994, The diagnosis of osteoporosis, J Bone Miner Res, 9, 1137, 10.1002/jbmr.5650090802 Kanis, 2008, Case finding for the management of osteoporosis with FRAX – assessment and intervention thresholds for the UK, Osteoporos Int, 19, 1395, 10.1007/s00198-008-0712-1 Kanis, 2010, Development and use of FRAX in osteoporosis, Osteoporos Int, 21, S407, 10.1007/s00198-010-1253-y Kanis, 1994, Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group, Osteoporos Int, 4, 368, 10.1007/BF01622200 Kanis, 2000, An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation, Osteoporos Int, 11, 192, 10.1007/s001980050281 Marshall, 1996, Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures, BMJ, 312, 1254, 10.1136/bmj.312.7041.1254 Stone, 2003, BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures, J Bone Miner Res, 18, 1947, 10.1359/jbmr.2003.18.11.1947 Schuit, 2004, Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study, Bone, 34, 195, 10.1016/j.bone.2003.10.001 Johnell, 2005, Predictive value of BMD for hip and other fractures, J Bone Miner Res, 20, 1185, 10.1359/JBMR.050304 Cummings, 2006, BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women, J Bone Miner Res, 21, 1550, 10.1359/jbmr.060708 Leslie, 2007, Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice, J Clin Endocrinol Metab, 92, 77, 10.1210/jc.2006-1415 Nelson, 2010, Screening for osteoporosis: an update for the U.S. Preventive Services Task Force, Ann Intern Med, 153, 99, 10.7326/0003-4819-153-2-201007200-00262 Hans, 2006, Skeletal sites for osteoporosis diagnosis: the 2005 ISCD Official Positions, J Clin Densitom, 9, 15, 10.1016/j.jocd.2006.05.003 Baim, 2008, Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference, J Clin Densitom, 11, 75, 10.1016/j.jocd.2007.12.007 Hans, 2008, Peripheral dual-energy X-ray absorptiometry in the management of osteoporosis: the 2007 ISCD Official Positions, J Clin Densitom, 11, 188, 10.1016/j.jocd.2007.12.012 Baim, 2005, Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry, J Clin Densitom, 8, 371, 10.1385/JCD:8:4:371 Lewiecki, 2006, DXA quality matters, J Clin Densitom, 9, 388, 10.1016/j.jocd.2006.07.002 Bell, 2009, Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data, BMJ, 338, b2266, 10.1136/bmj.b2266 Krieg, 2008, Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions, J Clin Densitom, 11, 163, 10.1016/j.jocd.2007.12.011 Nayak, 2006, Meta-analysis: accuracy of quantitative ultrasound for identifying patients with osteoporosis, Ann Intern Med, 144, 832, 10.7326/0003-4819-144-11-200606060-00009 Engelke, 2008, Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD Official Positions, J Clin Densitom, 11, 123, 10.1016/j.jocd.2007.12.010 1994, Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group, World Health Organ Tech Rep Ser, 843, 1 Kanis, 2008, A reference standard for the description of osteoporosis, Bone, 42, 467, 10.1016/j.bone.2007.11.001 WHO Scientific Group. Assessment of osteoporosis at the primary health care level Geneva (Switzerland). World Health Organization; Available from: http://www.who.int/chp/topics/Osteoporosis.pdf; 2007 [updated 2007; cited in May 2011]. Hind, 2007, Weight-bearing exercise and bone mineral accrual in children and adolescents: a review of controlled trials, Bone, 40, 14, 10.1016/j.bone.2006.07.006 Rizzoli, 2010, Maximizing bone mineral mass gain during growth for the prevention of fractures in the adolescents and the elderly, Bone, 46, 294, 10.1016/j.bone.2009.10.005 Chevalley, 2005, Interaction between calcium intake and menarcheal age on bone mass gain: an eight-year follow-up study from prepuberty to postmenarche, J Clin Endocrinol Metab, 90, 44, 10.1210/jc.2004-1043 Rowlands, 2004, Interactive effects of habitual physical activity and calcium intake on bone density in boys and girls, J Appl Physiol, 97, 1203, 10.1152/japplphysiol.00182.2004 Chevalley, 2008, High-protein intake enhances the positive impact of physical activity on BMC in prepubertal boys, J Bone Miner Res, 23, 131, 10.1359/jbmr.070907 Martyn-St James, 2010, Effects of different impact exercise modalities on bone mineral density in premenopausal women: a meta-analysis, J Bone Miner Metab, 28, 251, 10.1007/s00774-009-0139-6 Bonaiuti, 2002, Exercise for preventing and treating osteoporosis in postmenopausal women, Cochrane Database Syst Rev, CD000333 Korpelainen, 2006, Effect of impact exercise on bone mineral density in elderly women with low BMD: a population-based randomized controlled 30-month intervention, Osteoporos Int, 17, 109, 10.1007/s00198-005-1924-2 Sherrington, 2008, Effective exercise for the prevention of falls: a systematic review and meta-analysis, J Am Geriatr Soc, 56, 2234, 10.1111/j.1532-5415.2008.02014.x Shea, 2002, Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis, Endocr Rev, 23, 552, 10.1210/er.2001-7002 Prince, 2006, Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women, Arch Intern Med, 166, 869, 10.1001/archinte.166.8.869 Bischoff-Ferrari, 2007, Calcium intake and hip fracture risk in men and women: a meta-analysis of prospective cohort studies and randomized controlled trials, Am J Clin Nutr, 86, 1780, 10.1093/ajcn/86.6.1780 Bolland, 2008, Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial, BMJ, 336, 262, 10.1136/bmj.39440.525752.BE Bolland, 2010, Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis, BMJ, 341, c3691, 10.1136/bmj.c3691 Jackson, 2006, Calcium plus vitamin D supplementation and the risk of fractures, N Engl J Med, 354, 669, 10.1056/NEJMoa055218 Tang, 2007, Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis, Lancet, 370, 657, 10.1016/S0140-6736(07)61342-7 Bischoff-Ferrari, 2009, Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials, Arch Intern Med, 169, 551, 10.1001/archinternmed.2008.600 Sanders, 2010, Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial, JAMA, 303, 1815, 10.1001/jama.2010.594 Avenell, 2009, Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis, Cochrane Database Syst Rev, CD000227 Bischoff-Ferrari, 2009, Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials, BMJ, 339, b3692, 10.1136/bmj.b3692 Gillespie, 2009, Interventions for preventing falls in older people living in the community, Cochrane Database Syst Rev, CD007146 Parker, 2006, Effectiveness of hip protectors for preventing hip fractures in elderly people: systematic review, BMJ, 332, 571, 10.1136/bmj.38753.375324.7C Robinovitch, 2009, Hip protectors: recommendations for biomechanical testing – an international consensus statement (part I), Osteoporos Int, 20, 1977, 10.1007/s00198-009-1045-4 Cameron, 2010, Hip protectors: recommendations for conducting clinical trials – an international consensus statement (part II), Osteoporos Int, 21, 1, 10.1007/s00198-009-1055-2 Agulnek, 2009, Acute vertebral fracture, J Hosp Med, 4, E20, 10.1002/jhm.454 Sheon RP, Rosen H. Clinical manifestations and treatment of osteoporotic thoracolumbar vertebral compression fracture. Available from: www.uptodate.com/online/content/topic.do?topicKey=spinaldi/6255&selectedTitle=1%7E114&source=search_result [cited in May 2011]. Mazanec, 2003, Vertebral compression fractures: manage aggressively to prevent sequelae, Cleve Clin J Med, 70, 147, 10.3949/ccjm.70.2.147 Stadhouder, 2009, Nonoperative treatment of thoracic and lumbar spine fractures: a prospective randomized study of different treatment options, J Orthop Trauma, 23, 588, 10.1097/BOT.0b013e3181a18728 Francis, 2008, Back pain in osteoporotic vertebral fractures, Osteoporos Int, 19, 895, 10.1007/s00198-007-0530-x Rousing, 2009, Percutaneous vertebroplasty compared to conservative treatment in patients with painful acute or subacute osteoporotic vertebral fractures: three-months follow-up in a clinical randomized study, Spine (Phila Pa 1976), 34, 1349, 10.1097/BRS.0b013e3181a4e628 Wardlaw, 2009, Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial, Lancet, 373, 1016, 10.1016/S0140-6736(09)60010-6 Voormolen, 2007, Percutaneous vertebroplasty compared with optimal pain medication treatment: short-term clinical outcome of patients with subacute or chronic painful osteoporotic vertebral compression fractures. The VERTOS study, AJNR Am J Neuroradiol, 28, 555 Kasperk, 2005, Treatment of painful vertebral fractures by kyphoplasty in patients with primary osteoporosis: a prospective nonrandomized controlled study, J Bone Miner Res, 20, 604, 10.1359/JBMR.041203 Diamond, 2006, Clinical outcomes after acute osteoporotic vertebral fractures: a 2-year non-randomised trial comparing percutaneous vertebroplasty with conservative therapy, Med J Aust, 184, 113, 10.5694/j.1326-5377.2006.tb00148.x Alvarez, 2006, Percutaneous vertebroplasty: functional improvement in patients with osteoporotic compression fractures, Spine (Phila Pa 1976), 31, 1113, 10.1097/01.brs.0000216487.97965.38 Kallmes, 2009, A randomized trial of vertebroplasty for osteoporotic spinal fractures, N Engl J Med, 361, 569, 10.1056/NEJMoa0900563 Buchbinder, 2009, A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures, N Engl J Med, 361, 557, 10.1056/NEJMoa0900429 Klazen, 2010, Vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II): an open-label randomised trial, Lancet, 376, 1085, 10.1016/S0140-6736(10)60954-3 Pérez-Nuñez, 2010, Vertebroplastia y cifoplastia como tratamiento de las fracturas vertebrales osteoporóticas, Rev Osteopor Metab Miner, 2, 27 Hosking, 2005, Osteoporosis therapy: an example of putting evidence-based medicine into clinical practice, QJM, 98, 403, 10.1093/qjmed/hci070 Riggs, 2005, Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling, J Bone Miner Res, 20, 177, 10.1359/JBMR.041114 Lufkin, 1992, Treatment of postmenopausal osteoporosis with transdermal estrogen, Ann Intern Med, 117, 1, 10.7326/0003-4819-117-1-1 Greenspan, 2003, Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial, JAMA, 289, 2525, 10.1001/jama.289.19.2525 Rossouw, 2002, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial, JAMA, 288, 321, 10.1001/jama.288.3.321 Overgaard, 1989, Effect of salcatonin given intranasally on early postmenopausal bone loss, BMJ, 299, 477, 10.1136/bmj.299.6697.477 Chesnut, 2000, A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group, Am J Med, 109, 267, 10.1016/S0002-9343(00)00490-3 Lyritis, 1997, Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study, Acta Orthop Scand Suppl, 275, 112, 10.1080/17453674.1997.11744761 Johnell, 2002, Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis, J Clin Endocrinol Metab, 87, 985, 10.1210/jc.87.3.985 Cranney, 2002, Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis, Endocr Rev, 23, 524, 10.1210/er.2001-4002 Ettinger, 1999, Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators, JAMA, 282, 637, 10.1001/jama.282.7.637 Barrett-Connor, 2006, Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women, N Engl J Med, 355, 125, 10.1056/NEJMoa062462 Adomaityte, 2008, Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis, Thromb Haemost, 99, 338, 10.1160/TH07-07-0468 Barrett-Connor, 2009, Raloxifene and risk for stroke based on the framingham stroke risk score, Am J Med, 122, 754, 10.1016/j.amjmed.2009.01.033 De Villiers, 2011, Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial, Osteoporos Int, 22, 567, 10.1007/s00198-010-1302-6 Silverman, 2008, Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial, J Bone Miner Res, 23, 1923, 10.1359/jbmr.080710 Siris, 2011, Estimating bisphosphonate use and fracture reduction among U.S. women age 45 and older, 2001–2008, J Bone Miner Res, 26, 3, 10.1002/jbmr.189 Wells, 2008, Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women, Cochrane Database Syst Rev, CD003376 Wells, 2008, Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women, Cochrane Database Syst Rev, CD001155 Cranney, 2009, Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data, Osteoporos Int, 20, 291, 10.1007/s00198-008-0653-8 Jansen, 2009, Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies, Curr Med Res Opin, 25, 1861, 10.1185/03007990903035281 Cotte, 2010, Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis, Osteoporos Int, 21, 145, 10.1007/s00198-009-0930-1 Arboleya, 2010, Bisfosfonatos Watts, 1990, Intermittent cyclical etidronate treatment of postmenopausal osteoporosis, N Engl J Med, 323, 73, 10.1056/NEJM199007123230201 Harris, 1993, Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy, Am J Med, 95, 557, 10.1016/0002-9343(93)90350-X Ott, 1994, Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis, J Clin Endocrinol Metab, 78, 968, 10.1210/jc.78.4.968 Black, 2006, Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial, JAMA, 296, 2927, 10.1001/jama.296.24.2927 Bone, 2004, Ten years’ experience with alendronate for osteoporosis in postmenopausal women, N Engl J Med, 350, 1189, 10.1056/NEJMoa030897 Dansereau, 2009, In vitro disintegration studies of weekly generic alendronate sodium tablets (70mg) available in the US, Curr Med Res Opin, 25, 449, 10.1185/03007990802648903 Perkins, 2008, Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects, Clin Ther, 30, 834, 10.1016/j.clinthera.2008.04.018 Ringe, 2009, Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis, Rheumatol Int, 30, 213, 10.1007/s00296-009-0940-5 Body, 2010, Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club, Osteoporos Int, 21, 1657, 10.1007/s00198-010-1223-4 Harris, 1999, Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group, JAMA, 282, 1344, 10.1001/jama.282.14.1344 Reginster, 2000, Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group, Osteoporos Int, 11, 83, 10.1007/s001980050010 Watts, 2003, Risedronate prevents new vertebral fractures in postmenopausal women at high risk, J Clin Endocrinol Metab, 88, 542, 10.1210/jc.2002-020400 Harrington, 2004, Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis, Calcif Tissue Int, 74, 129, 10.1007/s00223-003-0042-4 Cranney, 2002, Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis, Endocr Rev, 23, 517, 10.1210/er.2001-3002 Brown, 2002, The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis, Calcif Tissue Int, 71, 103, 10.1007/s00223-002-2011-8 Chesnut, 2004, Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis, J Bone Miner Res, 19, 1241, 10.1359/JBMR.040325 Reginster, 2006, Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study, Ann Rheum Dis, 65, 654, 10.1136/ard.2005.044958 Stakkestad, 2008, Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension, Clin Rheumatol, 27, 955, 10.1007/s10067-007-0824-6 Harris, 2008, Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies, Curr Med Res Opin, 24, 237, 10.1185/030079908X253717 Sebba, 2009, Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis, Bone, 44, 423, 10.1016/j.bone.2008.10.052 Harris, 2009, Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study, Bone, 44, 758, 10.1016/j.bone.2009.01.002 Delmas, 2006, Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study, Arthritis Rheum, 54, 1838, 10.1002/art.21918 Von Moos, 2008, Renal safety profiles of ibandronate 6mg infused over 15 and 60min: a randomized, open-label study, Ann Oncol, 19, 1266, 10.1093/annonc/mdn038 Boonen, 2008, Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance, J Intern Med, 264, 315, 10.1111/j.1365-2796.2008.02010.x Black, 2007, Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis, N Engl J Med, 356, 1809, 10.1056/NEJMoa067312 Lyles, 2007, Zoledronic acid and clinical fractures and mortality after hip fracture, N Engl J Med, 357, 1799, 10.1056/NEJMoa074941 Colon-Emeric, 2010, Potential mediators of the mortality reduction with zoledronic acid after hip fracture, J Bone Miner Res, 25, 91, 10.1359/jbmr.090704 Arboleya, 2011, Efectos adversos de los bisfosfonatos, Reumatol Clin, 7, 189, 10.1016/j.reuma.2010.10.005 Abrahamsen, 2010, Adverse effects of bisphosphonates, Calcif Tissue Int, 86, 421, 10.1007/s00223-010-9364-1 Edwards, 2008, Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw, Lancet Oncol, 9, 1166, 10.1016/S1470-2045(08)70305-X Agencia Española del Medicamento y productos Sanitarios. Nota informativa de la AEMPS: recomendaciones para la prevención de la osteonecrosis del maxilar asociada al tratamiento con bisfosfonatos. Available from: http://www.aemps.es/actividad/alertas/usoHumano/seguridad/NI_2009-10_bisfosfonatos.htm; 2009 [updated 2009; cited in 2010]. Marx, 2007, Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment, J Oral Maxillofac Surg, 65, 2397, 10.1016/j.joms.2007.08.003 Baim, 2009, Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw, J Bone Miner Res, 24, 561, 10.1359/jbmr.090203 Abrahamsen, 2010, Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis, J Clin Endocrinol Metab, 95, 5258, 10.1210/jc.2010-1571 Black, 2010, Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur, N Engl J Med, 362, 1761, 10.1056/NEJMoa1001086 Koh, 2010, Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture?, J Orthop Trauma, 24, 75, 10.1097/BOT.0b013e3181b6499b Pazianas, 2010, Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis, Ther Clin Risk Manag, 6, 325 Rheumatology ACo. Denosumab. Available from: http://www.rheumatology.org/publications/hotline/2010_10_18_denosumab.asp; 2010 [updated October 2010; cited in April 2011]. Lewiecki, 2009, Denosumab update, Curr Opin Rheumatol, 21, 369, 10.1097/BOR.0b013e32832ca41c Cummings, 2009, Denosumab for prevention of fractures in postmenopausal women with osteoporosis, N Engl J Med, 361, 756, 10.1056/NEJMoa0809493 McClung, 2006, Denosumab in postmenopausal women with low bone mineral density, N Engl J Med, 354, 821, 10.1056/NEJMoa044459 Miller, 2008, Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial, Bone, 43, 222, 10.1016/j.bone.2008.04.007 Kendler, 2010, Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy, J Bone Miner Res, 25, 72, 10.1359/jbmr.090716 Brown, 2009, Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial, J Bone Miner Res, 24, 153, 10.1359/jbmr.0809010 Seeman, 2010, Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate, J Bone Miner Res, 25, 1886, 10.1002/jbmr.81 Lewiecki, 2007, Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD, J Bone Miner Res, 22, 1832, 10.1359/jbmr.070809 Bone, 2008, Effects of denosumab on bone mineral density and bone turnover in postmenopausal women, J Clin Endocrinol Metab, 93, 2149, 10.1210/jc.2007-2814 Genant, 2010, Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density, Bone, 47, 131, 10.1016/j.bone.2010.04.594 Reid, 2010, Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies, J Bone Miner Res, 25, 2256, 10.1002/jbmr.149 Tam, 1982, Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration, Endocrinology, 110, 506, 10.1210/endo-110-2-506 Hock, 1992, Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone, J Bone Miner Res, 7, 65, 10.1002/jbmr.5650070110 Whitfield, 2000, The parathyroid hormone, its fragments and analogues – potent bone-builders for treating osteoporosis, Expert Opin Investig Drugs, 9, 1293, 10.1517/13543784.9.6.1293 Ma, 2001, Catabolic effects of continuous human PTH (1–38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation, Endocrinology, 142, 4047, 10.1210/en.142.9.4047 European Medicines Agency. Forsteo. Available from: www.emea.eu.int/humandocs/humans/EPAR/forsteo; 2010 [updated 2010; cited in May 2011]. Schwietert, 1997, Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1–84)] in healthy postmenopausal volunteers, Clin Pharmacol Ther, 61, 360, 10.1016/S0009-9236(97)90169-7 Neer, 2001, Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis, N Engl J Med, 344, 1434, 10.1056/NEJM200105103441904 Cosman, 2001, Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal, J Bone Miner Res, 16, 925, 10.1359/jbmr.2001.16.5.925 Lindsay, 1997, Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis, Lancet, 350, 550, 10.1016/S0140-6736(97)02342-8 Greenspan, 2007, Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial, Ann Intern Med, 146, 326, 10.7326/0003-4819-146-5-200703060-00005 Body, 2002, A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis, J Clin Endocrinol Metab, 87, 4528, 10.1210/jc.2002-020334 Black, 2003, The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis, N Engl J Med, 349, 1207, 10.1056/NEJMoa031975 2008, Guías de práctica clínica en la osteoporosis postmenopáusica glucocorticoidea y del varón, Rev Clin Esp, 8, 1 2009, Guías de práctica clínica en la osteoporosis postmenopáusica glucocorticoidea y del varón, Rev Osteoporos Metab Miner, 1, 53 Jolette, 2006, Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1–84 in a 2-year study in Fischer 344 rats, Toxicol Pathol, 34, 929, 10.1080/01926230601072301 Tashjian, 2002, Commentary on clinical safety of recombinant human parathyroid hormone 1–34 in the treatment of osteoporosis in men and postmenopausal women, J Bone Miner Res, 17, 1151, 10.1359/jbmr.2002.17.7.1151 Subbiah, 2010, Of mice and men: divergent risks of teriparatide-induced osteosarcoma, Osteoporos Int, 21, 1041, 10.1007/s00198-009-1004-0 Peris, 2004, Toxicidad de la teriparatida, Rev Esp Reum, 3, 19 Bevilacqua, 2008, Teriparatide (1–34) vs. Parathyroid hormone (1–84) in women with severe postmenopausal osteoporosis: a randomized, head-to-head study, 48 Piemonte, 2009, The effect of recombinant PTH(1–34) and PTH(1–84) on serum ionized calcium, 1,25-dihydroxyvitamin D, and urinary calcium excretion: a pilot study, Calcif Tissue Int, 85, 287, 10.1007/s00223-009-9280-4 Marie, 1993, An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats, J Bone Miner Res, 8, 607, 10.1002/jbmr.5650080512 Chattopadhyay, 2007, The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation, Biochem Pharmacol, 74, 438, 10.1016/j.bcp.2007.04.020 Caverzasio, 2008, Strontium ranelate promotes osteoblastic cell replication through at least two different mechanisms, Bone, 42, 1131, 10.1016/j.bone.2008.02.010 Reginster, 2005, Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study, J Clin Endocrinol Metab, 90, 2816, 10.1210/jc.2004-1774 Meunier, 2003, Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis, Osteoporos Int, 14, S66, 10.1007/s00198-002-1341-8 Reginster, 2008, Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial, Arthritis Rheum, 58, 1687, 10.1002/art.23461 Reginster, 2009, Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years, Bone, 45, 1059, 10.1016/j.bone.2009.08.004 Breart, 2010, Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database, Osteoporos Int, 21, 1181, 10.1007/s00198-009-1050-7 Jonville-Bera, 2009, Strontium ranelate-induced DRESS syndrome: first two case reports, Allergy, 64, 658, 10.1111/j.1398-9995.2009.01940.x Pernicova, 2008, Rash, strontium ranelate and DRESS syndrome put into perspective. European Medicine Agency on the alert, Osteoporos Int, 19, 1811, 10.1007/s00198-008-0734-8 Grosso, 2008, Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions, Br J Clin Pharmacol, 66, 689 Bone, 2010, Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density, J Bone Miner Res, 25, 937 Eisman, 2011, Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect, J Bone Miner Res, 26, 242, 10.1002/jbmr.212 Stroup, 2009, Treatment with a potent cathepsin K inhibitor preserves cortical and trabecular bone mass in ovariectomized monkeys, Calcif Tissue Int, 85, 344, 10.1007/s00223-009-9279-x Isabel, 2010, The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor, Bioorg Med Chem Lett, 20, 887, 10.1016/j.bmcl.2009.12.083 Murphy, 2005, Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women, J Clin Endocrinol Metab, 90, 2022, 10.1210/jc.2004-2126 Hannon, 2010, Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial, J Bone Miner Res, 25, 463, 10.1359/jbmr.090830 Schaller, 2004, The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation, J Bone Miner Res, 19, 1144, 10.1359/JBMR.040302 Ominsky, 2010, Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength, J Bone Miner Res, 25, 948, 10.1002/jbmr.14 Li, 2010, Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass and bone strength in aged male rats, J Bone Miner Res, 25, 2647, 10.1002/jbmr.182 Padhi, 2011, Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody, J Bone Miner Res, 26, 19, 10.1002/jbmr.173 Bodine, 2009, A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein-1 stimulates bone formation, Bone, 44, 1063, 10.1016/j.bone.2009.02.013 Lotinun, 2010, A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys, Bone, 46, 1082, 10.1016/j.bone.2010.01.370 Fajardo, 2010, Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis), Bone, 46, 64, 10.1016/j.bone.2009.09.018 Ruckle, 2009, Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women, J Bone Miner Res, 24, 744, 10.1359/jbmr.081208 Black, 2005, One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis, N Engl J Med, 353, 555, 10.1056/NEJMoa050336 Rittmaster, 2000, Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate, J Clin Endocrinol Metab, 85, 2129, 10.1210/jc.85.6.2129 Deal, 2005, Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial, J Bone Miner Res, 20, 1905, 10.1359/JBMR.050714 Ste-Marie, 2006, Effect of teriparatide [rhPTH(1–34)] on BMD when given to postmenopausal women receiving hormone replacement therapy, J Bone Miner Res, 21, 283, 10.1359/JBMR.051020 Anastasilakis, 2009, Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide, Horm Metab Res, 41, 559, 10.1055/s-0029-1192035 Obermayer-Pietsch, 2008, Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment, J Bone Miner Res, 23, 1591, 10.1359/jbmr.080506 Boonen, 2008, Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis, J Clin Endocrinol Metab, 93, 852, 10.1210/jc.2007-0711 Wimalawansa, 1995, Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study, Am J Med, 99, 36, 10.1016/S0002-9343(99)80102-8 Lindsay, 1999, Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial, J Clin Endocrinol Metab, 84, 3076, 10.1210/jc.84.9.3076 Harris, 2001, Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women, J Clin Endocrinol Metab, 86, 1890, 10.1210/jc.86.5.1890 Finkelstein, 2003, The effects of parathyroid hormone, alendronate, or both in men with osteoporosis, N Engl J Med, 349, 1216, 10.1056/NEJMoa035725 Siris, 2005, Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study, J Bone Miner Res, 20, 1514, 10.1359/JBMR.050509 Maricic, 2010, The role of zoledronic acid in the management of osteoporosis, Clin Rheumatol, 29, 1079, 10.1007/s10067-010-1486-3 Lenart, 2009, Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study, Osteoporos Int, 20, 1353, 10.1007/s00198-008-0805-x Hochberg, 2002, Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents, J Clin Endocrinol Metab, 87, 1586, 10.1210/jc.87.4.1586 Chen, 2006, Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis, J Bone Miner Res, 21, 1785, 10.1359/jbmr.060802 International Society for Clinical Densitometry (ISCD). 2007 ISCD official positions. Middletown; Available from: http://www.iscd.org/; 2007 [updated 2007; cited in May 2011]. Delmas, 2007, Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis, J Clin Endocrinol Metab, 92, 1296, 10.1210/jc.2006-1526 1992 Ciria, 2001, Osteoporosis y grado de conocimiento de la misma en la población española, 101 Cannata, 1993, Epidemiología de las fracturas vertebrales, Rev Esp Enf Metab Oseas, 2, 2 Olmos, 1992, Incidence of hip fractures in Cantabria, Med Clin (Barc), 99, 729 Sosa, 1993, La fractura osteoporótica de cadera en España, Rev Esp Enf Metab Oseas, 2, 189 Peris, 1995, Aetiology and presenting symptoms in male osteoporosis, Br J Rheumatol, 34, 936, 10.1093/rheumatology/34.10.936 Peris, 1996, Male osteoporosis, Curr Opin Rheumatol, 8, 357, 10.1097/00002281-199607000-00014 Blanch, 1996, Osteoporosis in men, J Bone Min Res, 11, S231 Jackson, 1990, Osteoporosis in men: diagnosis, pathophysiology, and prevention, Medicine (Baltimore), 69, 137, 10.1097/00005792-199005000-00002 Goldray, 1993, Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH), J Clin Endocrinol Metab, 76, 288, 10.1210/jc.76.2.288 Morrison, 1994, Testosterone levels during systemic and inhaled corticosteroid therapy, Respir Med, 88, 659, 10.1016/S0954-6111(05)80062-9 Zhong, 2009, Anti-fracture efficacy of risedronic acid in men: a meta-analysis of randomized controlled trials, Clin Drug Invest, 29, 349, 10.2165/00044011-200929050-00007 Orwoll, 2010, Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study, J Bone Miner Res, 25, 2239, 10.1002/jbmr.119 Orwoll, 2003, The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis, J Bone Miner Res, 18, 9, 10.1359/jbmr.2003.18.1.9 Lewiecki, 2008, International society for clinical densitometry 2007 adult and pediatric official positions, Bone, 43, 1115, 10.1016/j.bone.2008.08.106 Peris, 2002, Clinical characteristics and etiologic factors of premenopausal osteoporosis in a group of Spanish women, Semin Arthritis Rheum, 32, 64, 10.1053/sarh.2002.33725 Bhalla, 2010, Management of osteoporosis in a pre-menopausal woman, Best Pract Res Clin Rheumatol, 24, 313, 10.1016/j.berh.2010.01.006 Peris, 2010, Osteoporosis en individuos jóvenes, Reumatol Clin, 6, 217, 10.1016/j.reuma.2009.01.014 Van Staa, 2002, The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis, Osteoporos Int, 13, 777, 10.1007/s001980200108 Canalis, 2007, Glucocorticoid-induced osteoporosis: pathophysiology and therapy, Osteoporos Int, 18, 1319, 10.1007/s00198-007-0394-0 Sambrook, 2007, Osteoporosis inducida por glucocorticoides, 361 Huizenga, 1998, A polimorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo, J Clin Endocrinol Metab, 144, 10.1210/jc.83.1.144 Sosa Henriquez, 2008, Guía de prevención y tratamiento de la osteoporosis inducida por glucocorticoides de la Sociedad Española de Medicina Interna, Rev Clin Esp, 208, 33, 10.1157/13115006 Saag, 1998, Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group, N Engl J Med, 339, 292, 10.1056/NEJM199807303390502 Wallach, 2000, Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy, Calcif Tissue Int, 67, 277, 10.1007/s002230001146 Reid, 2009, Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial, Lancet, 373, 1253, 10.1016/S0140-6736(09)60250-6 Saag, 2007, Teriparatide or alendronate in glucocorticoid-induced osteoporosis, N Engl J Med, 357, 2028, 10.1056/NEJMoa071408 Sambrook, 2007, Anabolic therapy in glucocorticoid-induced osteoporosis, N Engl J Med, 357, 2084, 10.1056/NEJMe0706770 Silverman, 2009, Glucocorticoid-induced osteoporosis, Curr Osteoporos Rep, 7, 23, 10.1007/s11914-009-0005-4 Adler, 2010, Glucocorticoid-induced osteoporosis: management update, Curr Osteoporos Rep, 8, 10, 10.1007/s11914-010-0003-6 Compston, 2010, Management of glucocorticoid-induced osteoporosis, Nat Rev Rheumatol, 6, 82, 10.1038/nrrheum.2009.259 Condon, 1978, Possible prevention and treatment of steroid-induced osteoporosis, Postgrad Med J, 54, 249, 10.1136/pgmj.54.630.249